Trade Vaxcyte Inc - PCVX CFD

About Vaxcyte Inc

Vaxcyte Inc. is a vaccine company, which is focused on developing vaccines designed to prevent or treat common and deadly infectious diseases worldwide. Its cell-free protein synthesis platform enables it to design and produce protein carriers and antigens. Its pipeline includes VAX-24, VAX-XP, VAX-A1 and VAX-PG. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine (PCV). The Company's second PCV candidate, VAX-XP, uses its modular platform and builds on the technical proof of concept established by VAX-24. VAX-A1 is a conjugate vaccine being developed for group A strep infections. Its VAX -PG is being developed as a protein vaccine for the treatment of periodontitis.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Vaxcyte Inc revenues was not reported. Net loss increased 12% to $100.1M. Higher net loss reflects General and administrative - Balancing increase of 49% to $18.5M (expense), Stock-based Compensation in SGA increase of 90% to $6.8M (expense), Stock-based Compensation in R&D increase from $1.9M to $4M (expense).